You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Anoro Ellipta contains two molecules specifically selected for their long duration of action, enabling once-daily dosing1-8

Anoro Ellipta contains umeclidinium (a LAMA) and vilanterol (a LABA). These molecules work together to promote bronchodilation: the LAMA blocks bronchoconstriction and the LABA stimulates bronchodilation.1

See how the molecules work

The LAMA and LABA in Anoro Ellipta work together to promote bronchodilation

Lama & Laba diagram Lama & Laba diagram
LAMA molecules

LAMA - Umeclidinium

LABA molecules

LABA - Vilanterol

Indication: Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

Dosing: The recommended (and maximum) dose is one inhalation of ANORO ELLIPTA (UMEC/VI 55/22 micrograms) once daily. The dose should be administered at the same time of the day each day to maintain bronchodilation.

Please refer to the SmPC for further information prior to prescribing.

You might also be interested in…

Head-to-head data vs. a LAMA

See data for Anoro Ellipta vs. a LAMA

Head-to-head data vs. a LAMA/LABA

See data for Anoro Ellipta vs. two other LAMA/LABAs

Dosing & the Ellipta device

Learn about the easy-to-use Ellipta device

References

  1. Anoro Ellipta SmPC 2019, Available at https://www.medicines.ie/medicines/anoro-ellipta-55-micrograms-22-micrograms-inhalation-powder-pre-dispensed-31288/spc
  2. Maleki-Yazdi M et al. Adv Ther 2016;33:2188–2199.
  3. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11:719–730.
  4. Laine DI. Exp Rev Clin Pharmacol 2010;3:43–53.
  5. Laine DI. J Med Chem 2009;52:2493–2505.
  6. Slack RJ et al. J Pharmacol Exp Ther 2013;344:218–230
  7. Hanania N et al. Chest 2012;142:119–127.
  8. Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro is a registered trademark of the GlaxoSmithKline group of companies.

Innoviva logo

PM-IE-UCV-WCNT-210015 January 2024